Zepbound(tirzepatide)
zepbound 2.5 MG in 0.5 ML Auto-Injector
Dosage & Administration
Dosage & Administration
drug label
Zepbound Prescribing Information
Financial Assistance
Financial Assistance Programs
Zepbound retails for $1,060 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Zepbound for significantly less. Review the program information below to determine what program can offer your patient the most benefits.Copay Card Program$25 Copay
Available for
commercial
Program Details
- Program Expires 12/31/2024
- $1800 Annual Cap
Forms
patient education
Zepbound Patient Education
Getting started on Zepbound
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
people also ask
Zepbound FAQs
Is there a pregnancy exposure registry for ZEPBOUND (tirzepatide)?Yes, there is a pregnancy exposure registry to monitor outcomes in pregnant women exposed to ZEPBOUND. Pregnant patients and healthcare providers can contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
What are the risks associated with ZEPBOUND during pregnancy?Weight loss is not recommended during pregnancy and discontinuation of ZEPBOUND is advised when pregnancy is recognized. Insufficient data exist to assess the risk of birth defects or miscarriage with tirzepatide use during pregnancy. Animal studies suggest potential fetal risks with exposure to tirzepatide.
Are there clinical considerations for pregnant patients using ZEPBOUND?Pregnant patients, including those with obesity, should gain appropriate weight as required during pregnancy. Weight loss is not advised in pregnant patients.
What animal data is available regarding tirzepatide exposure during pregnancy?Animal studies show fetal growth reductions and abnormalities in rats and rabbits given tirzepatide during pregnancy. These effects correlated with reductions in maternal body weights and food consumption.
Is ZEPBOUND recommended during lactation?There is no data on tirzepatide's presence in animal or human milk. The benefits of breastfeeding should be weighed against any potential adverse effects of ZEPBOUND on the breastfed infant or maternal condition.
Does ZEPBOUND impact oral hormonal contraceptives?ZEPBOUND may reduce the effectiveness of oral hormonal contraceptives due to delayed gastric emptying. Patients using these contraceptives should consider alternative or additional contraceptive methods for specific durations.
What is known about ZEPBOUND's use in pediatric patients and the elderly?ZEPBOUND's safety and effectiveness have not been established in pediatric patients below 18 years old. In elderly patients (65 years and older), no significant differences were observed in safety or effectiveness compared to younger adults.
Are dosage adjustments necessary for patients with renal or hepatic impairment?No dosage adjustment is recommended for patients with renal or hepatic impairment based on clinical studies, as no significant changes in tirzepatide pharmacokinetics were observed.
FAQ Data Source